ClinicalTrials.gg
CompletedNCT06251518InvidiCOUpdated Nov 16, 2026

Investigating the Effectiveness of Vimida

An interventional study of vimida in Long COVID and Post COVID-19 Condition, sponsored by Gaia AG. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Gaia AG · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now CompletedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany — 14 open to participants now, 17 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Germany.

Enrollment
8th of 28
176 · median 108
Started
2025
with 6 others
No phase
20 of 41
7 open now
Registered
31st of 41
by date

Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, this one is the 8th largest by enrollment of the 28 interventional ones that give a count, is one of 7 that started in 2025, is one of 20 with no phase, and was the 31st registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

14 of the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, or all of them as a file.
02

Study summary

This randomized controlled trial (RCT) with 176 patients suffering from fatigue after COVID-19 infection aimed to investigate the effectiveness of the unguided digital therapeutic vimida for reducing post-COVID-19 fatigue. Inclusion criteria were: male, female or non-binary, age ≥18 years, diagnosis of post-COVID-19 fatigue, ≥3 months since the last infection with COVID-19, fatigue severity score (cut-off) of ≥16 on the Chalder Fatigue Scale (CFQ-11), stable treatment in the past 30 days, consent to participation, and sufficient German language skills. Exclusion criteria were plans to change treatment in the upcoming 3 months, a known psychiatric or somatic condition that can explain the fatigue, and current participation in a multidisciplinary rehabilitation program aimed to ameliorate the consequences of COVID-19.

Patients were randomized and allocated to either an intervention group, in which they received access to vimida in addition to treatment as usual (TAU; n=88), or to a control group, in which they received access to TAU only (n=88).

The primary endpoint was fatigue symptoms, with three months post-allocation (T1) as the primary time point for assessing effectiveness. Six months post-allocation (T2) was used as the follow-up assessment of the endpoints. Secondary endpoints were depressive symptoms, health-related quality of life, work/social functioning, somatic symptoms, and anxiety symptoms.

03

Conditions studied

  • Long COVID
  • Post COVID-19 Condition
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male, female or non-binary
  • age ≥ 18
  • diagnosis of post-COVID-19 fatigue (ICD-10 U09.9 in conjunction with G93.3), secured via a telemedical visit
  • ≥ 3 months since COVID-19 infection that preceded fatigue symptoms
  • elevated levels of fatigue: cut-off of ≥ 16 on the CFQ-11
  • stable treatment in the past 30 days
  • consent to participation
  • sufficient knowledge of the German language

Exclusion criteria

Exclusion Criteria:

  • plans to change treatment in the upcoming 3 months
  • known somatic or psychiatric condition that can explain the fatigue (e.g., cancer, multiple sclerosis, severe depression)
  • current participation in a multidisciplinary rehabilitation program aimed at ameliorating the consequences of COVID-19
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    vimida + TAU

    Participants allocated to the intervention group received access to vimida in addition to treatment as usual (TAU). vimida is a digital health application designed for individuals with post-Covid conditions who suffer from fatigue, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by vimida are psychoeducation, activity and recovery, attention, stress management, sleep management, cognitive restructuring, and social resources. The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivational text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days.

    Behavioral: vimida

  • No intervention
    TAU

    Participants allocated to the control group received access to treatment as usual (TAU).

Interventions

  • Behavioralvimida

    Participants will receive access to the digital health intervention vimida in addition to TAU.

06

What researchers measure

Primary outcomes

  1. Fatigue symptom severity

    Chalder Fatigue Scale (CFQ-11). Total score ranging from 0-33; higher scores mean higher fatigue symptoms (worse outcome).

    Time frame: 3 months

Secondary outcomes

  1. Depressive symptoms

    Patient Health Questionnaire - 9 item version (PHQ-9). Total score ranging from 0-27; higher scores mean higher depressive symptoms (worse outcome).

    Time frame: 3 months

  2. Health-related quality of life

    Assessment of Quality of Life - 8 Dimensions (AQoL-8D). Total score ranging from 0-100; higher scores mean higher quality of life (better outcome).

    Time frame: 3 months

  3. Functioning

    Work and Social Adjustment Scale (WSAS). Total score ranging from 0-40; higher scores mean higher impairment (worse outcome).

    Time frame: 3 months

  4. Somatic symptoms

    Patient Health Questionnaire - 15 item version (PHQ-15). Total score ranging from 0-30; higher scores mean higher somatic symptoms (worse outcome).

    Time frame: 3 months

  5. Anxiety

    Generalized Anxiety Disorder Assessment (GAD-7). Total score ranging from 0-21; higher scores mean higher anxiety symptoms (worse outcome).

    Time frame: 3 months

Other outcomes

  1. Fatigue symptom severity

    Chalder Fatigue Scale (CFQ-11). Total score ranging from 0-33; higher scores mean higher fatigue symptoms (worse outcome).

    Time frame: 6 months

  2. Depressive symptoms

    Patient Health Questionnaire - 9 item version (PHQ-9). Total score ranging from 0-27; higher scores mean higher depressive symptoms (worse outcome).

    Time frame: 6 months

  3. Health-related quality of life

    Assessment of Quality of Life - 8 Dimensions (AQoL-8D). Total score ranging from 0-100; higher scores mean higher quality of life (better outcome).

    Time frame: 6 months

  4. Functioning

    Work and Social Adjustment Scale (WSAS). Total score ranging from 0-40; higher scores mean higher impairment (worse outcome).

    Time frame: 6 months

  5. Somatic symptoms

    Patient Health Questionnaire - 15 item version (PHQ-15). Total score ranging from 0-30; higher scores mean higher somatic symptoms (worse outcome).

    Time frame: 6 months

  6. Anxiety

    Generalized Anxiety Disorder Assessment (GAD-7). Total score ranging from 0-21; higher scores mean higher anxiety symptoms (worse outcome).

    Time frame: 6 months

07

Study locations

1 site
  • GAIA
    Hamburg, 22085, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Sep 2025, 6 months.

Of 243 interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2024
First posted
Feb 9, 2024
StartActual
Feb 13, 2025
Primary completionActual
Sep 4, 2025
CompletionActual
Dec 1, 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Enrollment
160 (estimated)→176 (actual)
Nov 16, 2026
Eligibility
1 inclusion criterion edited, 1 added; 1 exclusion criterion added
What changed in the criteria
Inclusion criteria
  • Editeddiagnosis of post-COVID-19 fatigue (ICD-10 U08.9, or U09.9 in conjunction with G93.3), secured via a telemedical visit
  • Addedstable treatment in the past 30 days
Exclusion criteria
  • Addedplans to change treatment in the upcoming 3 months
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Completed
    Enrollment 160 (estimated)→176 (actual)
    Eligibility 1 inclusion criterion edited, 1 added; 1 exclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • Editeddiagnosis of post-COVID-19 fatigue (ICD-10 U08.9, or U09.9 in conjunction with G93.3), secured via a telemedical visit
    • Addedstable treatment in the past 30 days
    Exclusion criteria
    • Addedplans to change treatment in the upcoming 3 months
    + 5 other changes: verification date, date precision, description, arm descriptions and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06251518
Lead sponsor
Gaia AG
Collaborators
Medical School Hamburg, Institut Long-Covid Rostock
Responsible party
Sponsor
First posted
Feb 9, 2024
Start date
Feb 13, 2025
Primary completion
Sep 4, 2025
Completion
Dec 1, 2025
Last update
Nov 16, 2026

Study contacts

Johanna Schröder, PhD
principal investigator · Medical School Hamburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion